{
    "nct_id": "NCT02520063",
    "official_title": "A Phase I/II Study of Preoperative (Neoadjuvant) Combination of Letrozole (Femara), Everolimus (Afinitor), and TRC105 in Postmenopausal Women With Newly Diagnosed Local or Locally Advanced Potentially Resectable Hormone-Receptor Positive and Her2 Negative Breast Cancer",
    "inclusion_criteria": "* Recent diagnosis of hormone receptor positive and HER2 negative breast cancer.\n* Stage 2 and 3 hormone receptor positive and HER2 negative breast cancer (stage T2-4 but not inflammatory, N0-2, M0).\n* Histological grade I, II or III according to the modified Bloom Richardson scale.\n* No prior treatment specific for breast cancer.\n* Postmenopausal status as defined by the National Comprehensive Cancer Network.\n* ECOG performance status < 2 (Karnofsky > 60%).\n* Must have signed study-specific informed consent.\n* Liver Function Tests < 2.5 times the upper normal limit (UNL).\n* ANC ≥ 1,500/mm3, platelets ≥ 100,000/mm3, Hemoglobin ≥ 10g%.\n* Renal function: serum creatinine < 1.5 institutional UNL or creatinine clearance > 40 cc/min.\nHealthy volunteers allowed\nMust be FEMALE\nMust have minimum age of 19 Years",
    "exclusion_criteria": "* Inflammatory breast cancer.\n* Pre- and peri-menopausal state.\n* Pregnancy.\n* Metastatic disease.\n* HER2 positive breast cancer by immunohistochemistry or FISH.\n* Triple negative breast cancer (hormone receptor and Her2 negative).\n* Disease that cannot be followed by imaging studies.",
    "miscellaneous_criteria": ""
}